ReviewFrontiers in cell and developmental biology2021
The Transcriptional Co-factor IRF2BP2: A New Player in Tumor Development and Microenvironment.
Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- In Depth Characterization of the Promoter Proximal Proteome of Single Copy Locus FOXP2.Molecular & cellular proteomics : MCP · 2026Article
- Tumor cell cycle regulation: integrated perspective of stage characteristics, regulatory networks, and signaling pathway intervention strategies.Molecular biomedicine · 2026Review
- Integrated transcriptomic and immune-associated network analysis of breast cancer patient-derived organoids reveals candidate inflammatory biomarkers.Frontiers in bioengineering and biotechnology · 2026Article
- Differences in the proteomic profiles of the eutopic endometrium in patients with internal and external adenomyosis.PLOS global public health · 2025Article
- Malate initiates a proton-sensing pathway essential for pH regulation of inflammation.Signal transduction and targeted therapy · 2024Article
- IRF2BP2 binds to a conserved RxSVI motif of protein partners and regulates megakaryocytic differentiation.Nature communications · 2024Article
- miR‑155 promotes an inflammatory response in HaCaT cells via the IRF2BP2/KLF2/NF‑κB pathway in psoriasis.International journal of molecular medicine · 2024Article
- Super-enhancer-driven IRF2BP2 enhances ALK activity and promotes neuroblastoma cell proliferation.Neuro-oncology · 2024Article
- RNA sequencing reveals molecular mechanisms of endometriosis lesion development in mice.Disease models & mechanisms · 2024Article
- B-cell intrinsic RANK signaling cooperates with TCL1 to induce lineage-dependent B-cell transformation.Blood cancer journal · 2024Article
- IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells.Nucleic acids research · 2024Article
- Case Report: A novel IRF2BP2 mutation in an IEI patient with recurrent infections and autoimmune disorders.Frontiers in immunology · 2023Article
- Novel frameshift variants expand the map of the genetic defects in IRF2BP2.Frontiers in immunology · 2023Article
- Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy.Rheumatology (Oxford, England) · 2022Article
- Proteomes of Residual Tumors in Curcumin-Treated Rats Reveal Changes in Microenvironment/Malignant Cell Crosstalk in a Highly Invasive Model of Mesothelioma.International journal of molecular sciences · 2022Article
- Development and characterization of type I interferon receptor knockout sheep: A model for viral immunology and reproductive signaling.Frontiers in genetics · 2022Article
- Fusion of the Genes for Interferon Regulatory Factor 2 Binding Protein 2 (In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon regulatory factor 2-binding protein 2 (IRF2BP2) encodes a member of the IRF2BP family of transcriptional regulators, which includes IRF2BP1, IRF2BP2, and IRF2BPL (EAP1). IRF2BP2 was initially identified as a transcriptional corepressor that was dependent on Interferon regulatory factor-2 (IRF-2). The IRF2BP2 protein is found in different organisms and has been described as ubiquitously expressed in normal and tumor cells and tissues, indicating a possible role for this transcriptional cofactor in different cell signaling pathways. Recent data suggest the involvement of IRF2BP2 in the regulation of several cellular functions, such as the cell cycle, cell death, angiogenesis, inflammation and immune response, thereby contributing to physiological cell homeostasis. However, an imbalance in IRF2BP2 function may be related to the pathophysiology of cancer. Some studies have shown the association of IRF2BP2 expression in hematopoietic and solid tumors through mechanisms based on gene fusion and point mutations in gene coding sequences, and although the biological functions of these types of hybrid and mutant proteins are not yet known, they are thought to be involved in an increase in the likelihood of tumor development. In this review, we address the possible involvement of IRF2BP2 in tumorigenesis through its regulation of important pathways involved in tumor development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.